
CSD
Cancer Center researchers Ajit Varki, Lubor Borsig, and Nissi Varki
have obtained evidence that the common anticoagulant drug heparin
diminishes metastasis of certain cancers in mice by interfering
with interactions between platelets (a type of normal blood cell,
shown in blue) and specific surface molecules on tumor cells (green).
In the absence of heparin, the platelets form a protective cloak
around the tumor cells (inset) and interfere with the work of immune
system monocytes (red). This work also indicates that the early
phase of these interactions is crucial for metastasis-a process
in which tumor cells from the primary site enter the bloodstream,
travel to distant tissues and establish new tumors. The UCSD researchers,
who reported their work in the March 13 Proceedings of the National
Academy of Sciences, say these findings make a compelling argument
for initiating clinical trials of heparin in patients with newly
diagnosed cancer. Supported by a grant from the National Cancer
Institute, this work involved an active collaboration with UCSD
Cancer Center laboratories for Histology (directed by Nissi Varki)
and Digital Imaging (directed by James Feramisco), and with SDSC
visualization researchers led by David Nadeau. The collaboration
with SDSC is supported by NSF through NPACI's Scalable Visualization
Toolkits alpha project. Color movies showing the effects of heparin
are available for PNAS subscribers on the journal Web site. The
Digital Imaging lab created a 3-D reconstruction of the microscopic
data, which was then turned into animated "fly-by" movies using
the Scalable Visualization Toolkit software for visualizing complex
3-D objects from large data sets, ranging from cellular structures
to the Orion Nebula.
|
|